Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Author:

Wang Xuan-Yi123ORCID,Mahmood Syed Faisal4,Jin Fang56,Cheah Wee Kooi7,Ahmad Muhammad8,Sohail Mian Amjad9,Ahmad Waheed10,Suppan Vijaya K.11,Sayeed Muneeba Ahsan12,Luxmi Shobha13,Teo Aik-Howe14,Lee Li Yuan15,Qi Yang-Yang12ORCID,Pei Rong-Juan16,Deng Wei6,Xu Zhong-Hui17,Yang Jia-Ming17,Zhang Yan17,Guan Wu-Xiang16,Yu Xiong18

Affiliation:

1. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China

2. Key Laboratory of Medical Molecular Virology of MoE & MoH, and Institutes of Biomedical Sciences, Fudan University, Shanghai, People’s Republic of China

3. Children’s Hospital, Fudan University, Shanghai, People’s Republic of China

4. Hospital of Aga Khan University, Karachi, Pakistan

5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, People’s Republic of China

6. Guangzhou Joincare Respiratory Medicine Co., Ltd, Guangzhou, People’s Republic of China

7. Department of Medicine and Clinical Research Centre, Taiping Hospital, Perak, Malaysia

8. Pulmonology & Critical care, Central Park Teaching Hospital, Lahore, Pakistan

9. Shifa International Hospitals Ltd, Islamabad, Pakistan

10. Avicenna Medical College, Lahore, Pakistan

11. Clinical Research Center, Sultan Abdul Halim Hospital, Kedah, Malaysia

12. Department of Infectious Diseases, Sindh Infectious Diseases Hospital and Research Centre, Dow University of Health Sciences, Karachi, Pakistan

13. Dow University of Health Sciences, Karachi, Pakistan

14. Penang General Hospital and Info Kinetics Clinical Research Centre, Pulau Pinang, Malaysia

15. CRC Seri Manjung Hospital, Perak, Malaysia

16. Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China

17. Livzon Mabpharm Inc., Zhuhai, People’s Republic of China

18. Joincare Pharmaceutical Group Industry Co., Ltd., Shenzhen, People’s Republic of China

Funder

Livzon Mabpharm Inc

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Reference43 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3